A Phase 2A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Antimalarial Pyrrolidinamide at Different Doses and Dose Durations, in Adult Patients With Uncomplicated P. Falciparum Malaria
Latest Information Update: 28 Apr 2026
At a glance
- Drugs MMV 367 (Primary)
- Indications Malaria
- Focus Adverse reactions
- Sponsors GSK
Most Recent Events
- 28 Apr 2026 New trial record